Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation Part 1. Pharmacokinetic and Pharmacodynamic Aspects
Journal Title: Міжнародний ендокринологічний журнал - Year 2015, Vol 7, Issue 71
Abstract
This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®). Gla-300 is a next generation basal insulin with a novel formulation of insulin glargin delivering the same amount of insulin, as glargine-100 (Gla-100, Lantus®) in 1/3 volume. Following the subcutaneous injection, pharmacokinetic and pharmacodynamic profiles of Gla-300 are more constant and prolonged (beyond 24 hours) compared with Gla-100 due to a more gradual and extended release of glargine from subcutaneous depot (Gla-300 forms a more compact subcutaneous depot with reduced surface area compared to Gla-100). The clinical efficacy and safety of Gla-300 in patients with type 1 and type 2 diabetes mellitus are discussed with an emphasis on recently released data from EDITION (the phase 3a) clinical trials. Gla-300 showed comparable glycaemic control and similar safety profile with lower incidence of hypoglycaemia events compared with Gla-100. Gla-300 provided flexible dosing of insulin (24 ± 3 h or morning vs evening) and was associated with less body weight gain.
Authors and Affiliations
V. V. Poltorak, N. A. Kravchun, M. Yu. Gorshunska
Keywords
Related Articles
- EP ID EP215662
- DOI -
- Views 158
- Downloads 0
Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: laboratory criteria for the diagnosis and control of treatment efficacy
Non-classic congenital adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency is one of the actual causes of hyperandrogenic manifestations at different age intervals. Timely diagnosis of the disease requires evalua...
Dynamics of acute phase indices in patients with rheumatoid arthritis combined with abdominal obesity, type 2 diabetes mellitus and arterial hypertension depending on Т-786С eNOS gene polymorphism following treatment
Background. The development of modern approaches to the pharmacotherapy of rheumatoid arthritis (RA) associated with abdominal obesity (AO), type 2 diabetes mellitus (DM 2) and arterial hypertension (AH) remains relevant...
Activation of intracellular enzyme systems under the influence of pathogenetic factors of oncogenesis in patients with type 2 diabetes mellitus
Background. It is proved that patients with diabetes mellitus (DM) have an increased risk of cancer. The main factors of oncogenesis in DM are obesity, cytokine imbalance, hyperinsulinemia (HI), hyperglycemia. These diso...
Nuances of insulin therapy in the treatment of the diabetic ketoacidosis
Background. The well-defined program of the insulin therapy is a guarantee of efficient treatment of a patient with the diabetic ketoacidosis. The approaches to the treatment varied depending on the gained experience, ho...
The role of adipocytokines in the development of non-alcoholic fatty liver disease in patients with hypertension and obesity
Background. Incidence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world along with epidemic of obesity (OB) and type 2 diabetes mellitus. The purpose of the study was to analyze the levels o...